Cadmium (Cd) is a notorious environmental pollutant known for its wide range of toxicities to organisms. Thus, the present study is designed to examine whether melatonin, a potent antioxidant, protects against Cd-induced oxidative damage in the heart, liver and kidney of rats. Cd treatment at a dose of 0.44 mg/kg for 15 days caused severe damage in all these organs. These included significantly increased activities of SGPT, SGOT, lactate dehydrogenase-1 and 5 and ALP and levels of total lactate, creatinine, lipid peroxidation, protein carbonyl content and reduced glutathione while the activities of superoxide dismutases, catalase, glutathione peroxidase, glutathione reductase and glutathione-S-transferase along with mitochondrial pyruvate dehydrogenase, isocitrate dehydrogenase, α-keto glutarate dehydrogenase, succinate dehydrogenase, NADH-cytochrome-c-oxidoreductase and cytochrome-c-oxidase were significantly reduced by Cd. However, if melatonin was given orally 30 min before Cd injection, all these alterations induced by Cd were significantly preserved by melatonin. Histological observations also demonstrated that Cd exposure caused cellular lesions, promoting necrotic or apoptotic changes. Notably, all these changes were significantly protected by melatonin. The results suggest that melatonin is a beneficial molecule to ameliorate Cd-induced oxidative damage in the heart, liver and kidney tissues of rats with its powerful antioxidant capacity, heavy metal chelating activity and competition of binding sites with Cd to the GSH and catalase.
INTRODUCTION
Cadmium (Cd) is a notorious toxic heavy metal that enters the environment from occupational (mining, smelting operations and electronics manufacturing) and nonoccupational exposure (1) . Humans are exposed to Cd from a variety of sources including cigarette smoke, consumption of contaminated sea food, shellfish, animal liver, water, cereals as well as from occupational and industrial exposure (2) . Cd is classified by IARC as a human carcinogen. The half-life of Cd in human body is more than 20 years and it is toxic even at low days. The rats were housed in animal facility of (University of Calcutta) with a light/dark cycle of 12/12h and temperature (20-26ºC) fed with standard diet and water ad libitum throughout the investigation (21) . Rats were handled as per the guidelines of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Ministry of Environment and Forest, Government of India, with the experimental protocol (IAEC-IV/Proposal/DB-06/2014/Dt.13/03/2014) approved by the Institutional Animal Ethics Committee (IAEC) of Department of Physiology, University of Calcutta.
Chemicals and reagents.
Cadmium chloride (CdCl2) and melatonin were purchased from Sisco Research Laboratories (SRL), Mumbai, India. All the other chemicals used in this study including the solvents were of analytical grade obtained from Sisco Research Laboratories (SRL), Mumbai, India; Qualigens (Germany); SD fine chemicals (India) and Merck Limited, Delhi, India. Different primary [SOD 1 (ab 16831); SOD 2 (ab13534), catalase (ab16731)] and secondary [Goat antirabbit IgG ALP-conjugated (ab97048)] antibodies were procured from Abcam Biotechnology Company (Abcam, USA), while β-actin (sc-130657) primary antibody was purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA).
Experimental design.
Male Wistar rats (n=48) were used for the present study. In the first experiment, 24 rats were equally divided into four groups. In the control group (n=6), rats were subcutaneously (s.c.) injected with vehicle [normal saline (0.9%)]. In the melatonin alone group (n=6), animals were treated (orally) with melatonin (10 mg/kg body weight) at every other day. In the Cd group (n=6), animals were subcutaneously (s.c.) injected with CdCl2 solution (0.44 mg/kg body weight) (22) at every other day. In the treatment group (n=6), rats were treated (orally) with melatonin (10 mg/kg body weight) 30 min prior to CdCl2 injection (0.44 mg/kg body weight s.c.) for every other day. The experiment was carried out for 15 days. Then, the animals were sacrificed by cervical dislocation following mild ether anesthesia and the organs were collected. Prior to cervical dislocation, blood was collected from the anesthezed animals by cardiac puncture, and the serum was prepared and stored at -80°C for further analyses. Immediately after organ collection, a small piece of each tissue (cardiac, hepatic and renal) was fixed in appropriate fixative solution for microscopic studies. The remaining tissues were stored at -80°C for further biochemical analyses. While, another 24 animals were further divided into four groups (n=6/group) as mentioned above and subjected for the estimation of their endogenous • OH (for details see supplementary file 1).
Preparation of tissue homogenates.
Ten percent (10%) heart, liver and kidney tissue homogenates were prepared freshly in 50 mM potassium phosphate buffer (pH 7.4), using a Potter-Elvehjem glass homogenizer (23) . The required portion of the homogenates was used for the measurement of enzyme activities and Western blot analysis.
Measurement of activities of serum enzymes associated with functions of heart, liver and kidney.
The activities of enzymes of SGPT and SGOT were measured following the method of Reitman and Frankel (1957) (24) . The enzyme activities were expressed as IU/L.
The activities of lactate dehydrogenase-1 (LDH1), lactate dehydrogenase-5 (LDH5) and total lactate dehydrogenase (TLDH) in serum were estimated following the method described by Strittmatter et al. (1965) (25) with some modifications (26) . The enzyme activities were expressed as IU/L.
The serum-specific marker alkaline phosphatase (ALP) was measured following the method of Kind and King's (27) . The levels were expressed as KA units.
Blood creatinine level was estimated by the method of Folin and Wu (28) with minor modifications. The results were expressed as mg (%). The blank and standard samples were prepared using distilled water. Creatinine was dissolved in acid solution.
2.6. Measurement of the biomarkers of oxidative stress in heart, liver and kidney.
The reduced glutathione (GSH) contents in the same tissues were estimated following the method of Sedlac and Lindsey (1968) (29) with some modifications (30) . The values were expressed as nmoles/mg tissue protein.
Lipid peroxidation (LPO) level was determined following the method of Buege and Aust (1978) (31) with some modifications as adopted by Bandyopadhyay et al. (2004) (30) . Levels were expressed as nmoles of TBARS/mg of tissue protein.
The protein carbonyl (PCO) content in the same tissues was estimated by DNPH assay following the method of Levine et al. (1994) (32) . The absorbance was recorded at 370 nm using a UV/VIS spectrophotometer. The values were expressed as nmoles/mg tissue protein.
Measurement of activities of antioxidant enzymes.
The activity of Cu-Zn-SOD and mitochondrial Mn-SOD were measured by pyrogallol autoxidation method of Marklund and Marklund (1974) (33) . Change in absorbance/min was recorded at 420 nm and the enzyme activity was expressed as units/mg of tissue protein.
The activity of catalase (CAT) was determined following the method described by Beers and Sizer (34) with some modifications as adopted by Chattopadhyay et al. (2003) (35) . The enzyme activity was measured at 240 nm and expressed as nmoles H2O2 consumed/mg of tissue protein.
Determination of the protein expression of antioxidant enzymes with Western Blot analysis.
Heart, liver and kidney tissue homogenates were prepared for western blot analysis of CuZn-SOD, Mn-SOD, CAT and β-actin proteins following the method described earlier by Bandyopadhyay et al. [30] . In brief, sixty microgram of proteins were loaded in each well and subjected to SDS-PAGE (10%) following the method of Laemmli (36) . After transferring the proteins to PVDF membrane (Immobilon P, Sigma), it was incubated in blocking solution for 1 h. Following the proper washes, the immunoblots were incubated overnight in respective primary antibody (dilution 1:2000) at 4°C. After completion of incubation, the membrane was washed 3 times and the blot was incubated in secondary antibody (dilution 1: 3000) for 2 h at room temperature. The membrane was subjected to incubation in the presence of the substrate (BCIP/NBT) after proper washing. Finally, intensity of individual band of each immunoblot was normalized by the intensity of β-actin (internal control) and the relative density of the individual bands was quantified by densitometry using ImageJ software (NIH, Bethesda, MD, USA).
2.9.
Measurement of activities of different glutathione-dependent enzymes in rat heart, liver and kidney.
The activity of glutathione peroxidase (GPx) was determined following the method as described by Paglia and Valentine (1967) (37) with some modifications as adopted by Chattopadhyay et al. (35) . The enzyme activity was measured at 340 nm and expressed as nmoles/mg tissue protein.
The activity of glutathione reductase (GR) was measured according to the method of Krohne-Ehrichet al. (38) . The change in absorbance was recorded at 340 nm using a UV/VIS spectrophotometer and the specific activity of the enzyme was expressed as nmoles/mg tissue protein.
The glutathione-S-transferase (GST) activity was measured spectrophotometrically at 340nm following the method of Habig et al. (39) . The enzyme activity was expressed as Units/mg tissue protein.
2.10. Determination of the activities of glucose metabolic enzymes in heart, liver and kidney tissue homogenates.
The cardiac, hepatic and renal tissues were homogenized (10%) in chilled phosphate buffer (50 mM, pH 7.4) with a Potter Elvenjem glass homogenizer (Belco Glass, Inc., Vineland, NJ, USA). The homogenates were centrifuged at 5000 x g for 10 min and the supernatant was further centrifuged at 12000 x g for 15 min to obtain the mitochondrial fraction. The pellet was resuspended in appropriate buffer and used for measuring the activities of following enzymes. The activity of pyruvate dehydrogenase (PDH) was determined spectrophotometrically at 340 nm following the method of Chretien et al. (1995) (40) with some modifications (41) . The activity of isocitrate dehydrogenase (ICDH) and α-ketoglutarate dehydrogenase (α-KGDH) were determined following the method as described by Duncan et al. (42) . The method of Veeger et al. (43) was used to measure the activity of succinate dehydrogenase (SDH). The enzyme activities were recorded at 420 nm and were expressed as units/mg tissue protein.
11. Determination of the activities of mitochondrial respiratory chain enzymes in heart, liver and kidney.
The activities of NADH-Cytochrome c oxidoreductase and cytochrome c oxidase were determined following the method of Goyal and Srivastava (44) . The activities were recorded spectrophotometrically at 565 and 550 nm, respectively for both enzymes. The activities of the enzymes were expressed as units/mg tissue protein.
Determination of the activities of xanthine oxidase (XO) and xanthine dehydrogenase (XDH).
The method of Greenlee and Handler (1964) (45) along with some modifications (46) was used to determine the activity of XO. The activity of XDH was also measured spectrophotometrically following the method of Strittmatter et al. (25) . The enzyme activities were expressed as milliUnits/mg tissue protein. http://www.melatonin-research.net 2.14. Histological studies.
Measurement of endogenous • OH.

Hematoxylin and eosin (H & E) assay.
A portion of the extirpated heart, liver and kidney tissues were fixed, respectively in 10% formalin and embedded in paraffin following routine histological procedure. The tissue sections (5 μm thick) were prepared and stained with H&E. The stained samples were examined under a Leica microscope and the images were captured with a digital camera attached to it (47).
Quantification of tissue fibrosis by confocal microscopy.
The tissue sections (5 μm thick) were stained with Sirius red (Direct Red 80; Sigma Chemical Co, Louis, MO, USA) according to the method of Roy et al. (47) and imaged with a laser scanning confocal system (Zeiss LSM 510 META, Germany) and the stacked images through multiple slices were captured. Four slides of each tissue from an individual rat in different groups were prepared. The digitized images were analyzed using an image analysis system (Image J, NIH Software, Bethesda, MI) and the total collagen area fraction was measured and expressed as the % collagen volume.
Morphological analysis with scanning electron microscopy (SEM).
Immediately after dissection, the heart, liver and kidney tissues and the mitochondria isolated from each tissue were fixed in 2.5% cold glutaraldehyde for 24-48 h, then the SEM analysis was performed following the method of Watanabe et al. (48) with some modifications (49) . Briefly, the tissue sections, as well as the mitochondrial smear, were washed 3-4 times in phosphate buffer (50 mM, pH 7.2), then, the samples were dehydrated through ascending grades of alcohol treatment (30, 50, 70, 90 , and 100%; each for 10 min). The dehydrated samples were embedded in iso-amyl alcohol and then placed at 4ºC until the iso-amyl alcohol is solidified. The frozen samples were then dried under vacuum and evaluated by SEM (Zeiss Evo 18 model EDS 8100).
Estimation of Cd content in cardiac, hepatic and renal tissues with atomic absorption spectrophotometry (AAS).
The cardiac, hepatic and renal tissue samples were processed, respectively and the Cd content was measured as per the protocol mentioned in the cookbook of the Sophisticated Analytical Instrument Facilities' (SAIF), "Thermo Scientific iCE 3000 Series Atomic Absorption Spectrometer" at the Bose Institute, Kolkata. The samples were prepared with nitric acid (65%) for total dissolution as described by Mitra et al. (50) . The Cd content was expressed as μg/g tissue.
Binding analysis of GSH and CAT with Cd and melatonin in a cell-free/chemical system through isothermal titration calorimetry (ITC).
The binding analyses of GSH or CAT with Cd and melatonin were analyzed by ITC in a cell-free/chemical system using Microcal ITC-200, Malvern, UK. For this assay, in the sample cell, 0.3 ml of CAT (4 ×10 −9 mM) or GSH (4mM) was titrated, respectively with 0.06 ml of 0.1 mM CdCl2 or/and melatonin (40μM for GSH and 80 μM for catalase, respectively) as ligands in specific combinations as follows: (i) CdCl2 alone (ii) melatonin alone (iii) combination of CdCl2 and melatonin. Melatonin binding with Cd was also examined. In brief, 0.3 ml of melatonin (1 × 10 −3 mM) in the sample cell was titrated against 0.06 mL of 0.2mM CdCl2. For a single run, titration was conducted with 20 injections of each ligand (2 μl each) with 150 sec of interval between two successive injections for approximately 1 h at 37°C. Following the titration, data analysis was performed using Origin 7.0 software (Microcal LLC).
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Estimation of protein content.
The concentration of proteins in heart, liver and kidney tissue homogenates were estimated, respectively by the method of Lowry et al. (51) using the bovine serum albumin as the standard.
Statistical evaluation.
Each experiment was repeated thrice with different rats. The data for various biochemical parameters were expressed as means ± S.E.M. The statistical significance of the data has been determined using one-way analysis of variance (ANOVA) after ascertaining the homogeneity of variances between the treatments and significant difference between the groups were evaluated by Scheffes' test. The results were considered statistical significance at p<0.05. All statistical analyses were made using Microcal Origin version 6.0 for Windows.
RESULTS
3.1. Effects of melatonin on the activities of enzymes associated with functions of heart, liver and kidney in rats treated with/without Cd.
Cd treatment in rats significantly elevated the activities of their serum SGOT, SGPT, LDH1, LDH5, total LDH and ALP as well as the levels of creatinine, compared to the control animals ( Fig. 1) . Melatonin treatment alone did not modify these parameters compared to controls. However, melatonin pre-treatment before Cd injection significantly suppressed the elevation of activities in these serum enzymes induced by the Cd. In most of the cases, melatonin rescued the activities of these enzymes in Cd treated animals back to the levels similar to that of the control group (Fig. 1 ). The levels of LPO and PCO in the cardiac, hepatic and renal tissues were significantly (p<0.001) elevated in Cd-treated rats compared to their controls (Fig. 2) . In contrast, the content of GSH was significantly reduced by Cd treatment compared to the control group. Melatonin treatment alone did not cause obvious alterations on these parameters. However, melatonin pretreatment before the Cd injection significantly reversed the alterations of these oxidative biomarkers induced by Cd (Fig. 2) . Cd-treatment significantly (p<0.001) decreased the activities of Cu-Zn-SOD in the cardiac and renal tissues, but increased its activity in hepatic tissue. Melatonin pre-treatment before Cd injection preserved the activities of Cu-Zn-SOD to their respective control values in all the studied tissues (Fig. 3A) . For the activity of Mn-SOD, a significant decrease in cardiac tissue and increases in hepatic and renal tissues was observed after Cd treatment. Melatonin treatment almost completely reversed the alterations of Mn-SOD activity induced by the Cd (Fig. 3B) . On the other hand, CAT activities were significantly (p<0.001) decreased in the hepatic and renal tissues, but increased in the cardiac tissue after Cd treatment compared to the control. Melatonin treatment reversed these alterations caused by Cd to the levels similar to the control (Fig. 3C) . The gene expressions (protein content) analyses on these enzymes showed that the upregulation and downregulation of these proteins exhibited the similar patterns as their activities in all tissues treated with Cd alone or with Cd plus melatonin. The results are shown in Fig. 3 ; D-L. 
Data were expressed as mean ± S.E.M. (n=6) (A) Cu-Zn-SOD, (B) Mn-SOD and (C) CAT activities. (D) the representative images of protein expressions of Cu-Zn-SOD, Mn-SOD and CAT and (E-L) their relative protein levels in different tissues of rat treated with CdCl2 (0.44 mg/kg) and/or, melatonin (10 mg/kg). # p<0.001versus C; * p<0.001 versus Cd.
Effects of melatonin on the activities of glutathione-synthetic enzymes in heart, liver and kidney tissues of rats treated with/without Cd.
Cd Treatment significantly (p<0.001) suppressed the activity of GR in the cardiac, hepatic and renal tissues compared to the control (Fig. 4) . Pre-treatment with melatonin (10 mg/kg) elevated GR activity which was suppressed by Cd to the level of control in all the studied tissues. On the contrary, the different responses were noted in the activities of GPx and GST. Cd treatment caused a significant increase in the activities of GPx and GST in the cardiac, hepatic and renal tissues compared to their respective controls while melatonin pre-treatment before Cd injection preserved their activities to the similar levels of controls in all tissues (Fig.  4) . Melatonin alone did not alter the activities of these enzymes compared to control. 
Data were expressed as mean ± S.E.M. (N=6). (A) GR, (B) GPx, (C) GST in the cardiac, hepatic and renal tissues of rats treated with CdCl2 (0.44 mg/kg) and/or, melatonin (10 mg/kg
Effects of melatonin on the activities of Krebs cycle as well as mitochondrial respiratory chain enzymes in heart, liver and kidney tissues of rats treated with/without Cd.
The activities of PDH, ICDH, α-KGDH) and SDH in the heart, liver as well as kidney significantly reduced by Cd treatment. However, the reduced activities of these enzymes caused by Cd were almost completely recovered to their control levels with melatonin pre-treatment (Fig. 5. A-D) .
On the other hand, Cd at a dose of 0.44 mg/kg also significantly decreased the activities of mitochondrial respiratory chain enzymes including NADH cytochrome c reductase and cytochrome oxidase (Fig. 5 . E-F) while melatonin pre-treatment blocked these alterations induced by the Cd in all the tissues studied. Melatonin alone had little effects on the activities of these enzymes. 3.6. Effects of melatonin on the activities of pro-oxidant enzymes and levels of endogenously generated ·OH in heart, liver and kidney tissues of rats treated with/without Cd.
Data were expressed as mean ± S.E.M. (n=6). (A) PDH, (B) ICDH, (C) α-KGDH, (D) SDH, (E) NADH cytochrome c reductase activity and (F) cytochrome oxidase in the cardiac
The activities of XO, XDH, the ratio of XO/XDH, total activity of XO+XDH and the ratio of XO/(XO+XDH) as well as the level of endogenous ·OH were significantly (p<0.001) increased (Fig. 6 ) in the cardiac, hepatic and renal tissues of rats treated with CdCl2 (0.44 mg/kg) while all of these changes were significantly inhibited with melatonin pre-treatment (Fig. 6) . Melatonin alone did not modify there parameters compared to their respective controls. Figure 6 : Effects of melatonin on the activities of pro-oxidant enzymes and levels of endogenously generated ·OH in heart, liver and kidney tissues of rats treated with/without Cd.
Data were expressed as mean ± S.E.M. (n=6). (A) XO, (B) XDH, (C) ratio of XO/XDH ratio, (D) total enzyme activity of XO+XDH, (E) ratio of XO/(XO+XDH) and (F) level of . OH in the cardiac, hepatic and renal tissues of rats treated with CDCl2 (0.44 mg/kg) and/or melatonin (10 mg/kg). # p<0.001 vs. Control group; * p<0.001 vs. Cd-treated group.
Effects of melatonin on the histological alterations in heart, liver and kidney tissues of rats treated with/without Cd.
In liver, H&E staining analysis showed that Cd caused portal and periportal lymphocyte infiltration along with necrosis of periportal hepatocyte. In heart and kidney, Cd resulted in the myocardial fiber necrosis and renal tissue large glomerulus with nodular mesangial expansion, respectively (Fig. 7A) . The morphological pathologies caused by Cd were largely provented by melatonin pre-treatment. The acid sirius staining analysis also showed that Cd treatment caused a depletion of collagen content in heart while collagen content almost recovered to the control level when the rats were pre-treated with melatonin ( Fig. 7. B-E) . In the liver and kidney, a deposition of collagen especially around the central vein of the hepatic lobule and Melatonin Research (Melatonin Res.) http://www.melatonin-research.net renal malphigian capsule was observed and this indicated tissue fibrosis. Again, melatonin pretreatment significantly reduced these abnormalities caused by Cd (Fig. 7. B-E). Melatonin alone did not modify the morphological appearances of these tissues compared to controls. In this study, SEM was used to analysis the detailed surface architectural alterations of the tissues. In heart, the irregularities in the branching pattern of the cardiac muscle fibers were observed after Cd treatment and these myofibrillar collagen fibers were cross-linked to each other to form a complicated matrix network (Fig. 8A) . In hepatic tissue, the dilated central veins, distortion in the polyhedral arrangement of hepatocytes with profound tissue necrosis were identified in Cd-treated group (Fig. 8A) . In renal tissue, shrunken glomerular tufts accompanied by loss of structural cohesion were the cases in Cd-treated group (Fig. 8A) . In addition, mitochondria isolated from heart and liver exhibited the small membrane blebs with disrupted cristae, vacuolation and the rough and ruptured surface (Fig. 8B) . Similarly, the mitochondria isolated from renal tissues also displayed perforated surface and convoluted membranes with the surface covering blebs due to markedly contracted cells (Fig. 8B) . All of these abnormalities induced by Cd were significantly prevented with melatonin pre-treatment. 
Effect of melatonin on the concentrations of Cd in heart, liver and kidney tissues.
The concentrations of Cd in the cardiac, hepatic and renal tissues were significantly (p<0.001) increased in the rats treated with CdCl2 (Fig. 9) . Pre-treatment with melatonin (10 mg/kg BW.) significantly reduced the Cd loads in heart, liver and renal tissues by 56.44%, 31.84% and 44.54%, respectively (Fig. 9 ). ITC data chart depicts the binding pattern of GSH with Cd and melatonin, respectively. Upon titration of GSH with Cd, an exothermic interaction with steady saturation of heat change was observed (Fig. 10A) . However, GSH with melatonin showed an exothermic interaction with the sequential binding pattern which was fitted to five sites sequential binding model with gradual saturation (Fig. 10B) . When titration of GSH with a combination of melatonin and Cd, a significant single site binding with significant heat change was observed (area under the curve) as a progressive saturation with time (Fig. 10C) .
As to the titration of CAT with Cd injection, a sequential binding pattern with low-intensity binding was observed and this binding was characteristic with gradual saturation of binding energy (Fig. 10D) . However, titration of CAT with melatonin displayed a significant one site binding with high initial heat change which slowed down with time (Fig. 10E) . Interestingly, upon titration of CAT with a combination of Cd and melatonin, an endothermic reaction was observed and this reaction characterized a competition between Cd and melatonin for the same binding site in CAT until the gradual saturation was reached (Fig. 10F ). 
The representative ITC profiles of GSH and CAT with Cd and melatonin. In the heat changes vs. time titration curves, each peak represents an injection of ligand into the sample cell that contains (A) GSH vs Cd as ligand, (B) GSH vs melatonin as ligand, (C) GSH vs Cd and melatonin as ligands, (D) CAT vs Cd as ligand, (E) CAT vs melatonin as ligand and (F) CAT vs Cd and melatonin as ligands. The amount of heat change per second (ΔH) is represented by the area under the curve and the heat change in terms of kcal mol −1 of injectant against molar ratio is shown below curve of each figure, respectively. Values of ΔH, ΔS and no. of sites were expressed in terms of mean ± S.E.
DISCUSSION
Cd is a toxic heavy metal with a widely spreading environmental contamination in the industrial or developing countries. This pollutant is classified as a human carcinogen of Group-1 (3). It mainly deposits in the soft tissues of body including the heart, liver and kidneys and initiates oxidative stress in these tissues. Due to its long half-life in biosystem, its low level in body still causes significant damage if it is not properly treated (2) . Unfortunately, there is no specific remedy available for Cd toxicity currently (3). The antioxidant treatment seems to be a promising alternative (8) . Thus, to identify the effective antioxidants for the Cd toxicity is not only necessary but urgent. Melatonin is a potent free radical scavenger and antioxidant (19) . Several studies have documented that melatonin reduces Cd associated oxidative damages in organisms including animals and even in plants (16, 30, 52, 53) . However, the underling mechanisms remain to be clarified.
In the current study, the effects of melatonin on the Cd toxicity in heart, liver and kidneys of rats were systemically investigated and the new evidence has emerged to further understand protective mechanisms of melatonin on Cd toxicity.
The study results confirmed that Cd administration to rats resulted in a wide range of injuries in the heart, liver and kidney tissues and this was indicated by the significantly increased serum activities of SGOT, SGPT, LDH1, LDH5, total LDH and ALP and levels of LPO and PCO in rats after Cd treatment. The morphological studies further confirmed the biochemical results, that is, the gross-and ultra-structures of these tissues were significantly disturbed by Cd toxicity. These multiple tissue injuries could be largely attributed to the oxidative stress since Cd treatment significantly increased the ROS, particularly the ·OH in the respective tissues tested. This imbalance of ROS production probably was a result of that Cd suppressed activities of several important antioxidant enzymes including Cu-Zn SOD, Mn-SOD, CAT, GR, GPx and GST. The Cu-Zn-SOD and Mn-SOD participates in dismutation of superoxide anion to H2O2 in cytosol and also in mitochondria, respectively; then, the CAT converts the H2O2 to harmless water and oxygen. The GR, GPx and GST collectively produce GSH, one of the most important intracellular antioxidants. Without the orchestral of these antioxidant enzymes the oxidative stress in Cd distributed tissues is inevitable.
The results showed that all damages in the tested tissues were partially or completely protected by melatonin pre-treatment. This is mainly due to the potent antioxidant capacity of melatonin and also its other functions which will discussed later. Melatonin not only directly scavengers a broad spectrum of ROS but also stimulates the activities of a variety of antioxidant enzymes (46) as well as suppresses the activities of pro-oxidant enzymes [46] as we observed in the study. We also observed that melatonin significantly upregulated the gene expressions of Cu-Zn-SOD, Mn-SOD, CAT which could further contributed to increase in their activities.
As we know that the mitochondria are the major source of the ROS (54, 55) . Thus, the effects of Cd and melatonin on mitochondrial metabolisms and mitochondrial morphology were specifically investigated. Cd caused the disturbance of mitochondrial metabolism and deformed their morphology. These alterations were preserved by melatonin. Melatonin not only increased the activities of Krebs cycle enzymes but also the enzymes of ETC which would promote the electron transportation and reduce the electron leakage from the ETC, thus, reduce the ROS formation. It has been well documented that melatonin is a mitochondrial targeted antioxidant [55] and it is generated, metabolized and functioned in mitochondria in all cells (56) . The exogenously administrated melatonin in rats can be concentrated in the mitochondria of heart, liver and kidneys by a specific transporter located in the mitochondrial membrane (19) and functions as a mitochondrial antioxidant. These antioxidant activities of melatonin mentioned above are not limited to itself and its many metabolites also possess the similar activities as melatonin (57) . This feature of melatonin magnifies its antioxidative capacity compared to other antioxidants.
In addition, the novel aspects of melatonin to protect against Cd toxicity have also be uncovered in the current study. It was reported that Cd could bind to GSH (58) and the interaction of Cd with protein-bound sulfhydryl group of GSH may be the primary cause for Cd toxicity in organisms (59) . The results from the ITC study revealed that melatonin also potentially possessed the thermodynamically favorable binding sites with Cd indicated by an increase of entropy upon their binding. Interestingly, when both melatonin and Cd were incubated with GSH, a steady as well as thermodynamically favored binding among them throughout the reaction was favorable to melatonin, thus to protect the GSH from Cd induced oxidation. The similar reaction was also found in the CAT binding study. Wang et al. (60) reported that the misfolding and alterations in the activity of CAT might be due to the interaction of Cd with this enzyme. Our result showed that melatonin and Cd competed for the same binding site in CAT. It is likely that melatonin discharges the Cd in the CAT binding site by its metal chelating property (57, 61) . This speculation was also confirmed by the Cd content analysis. A profound accumulation of Cd content in heart, liver and kidney tissues was noted in Cd-treated groups compared to control, which might be due to its excessive accumulation and long half-life in soft tissues (27) . Pre-treatment with melatonin significantly reduced this Cd accumulation in all tissues tested. The heavy metal chelating activity of melatonin can plausibly explain this observation.
Collectively, all these actions of melatonin mentioned above are attributed its profound protective effects on Cd associated tissue injuries. The potentially underlying mechanisms were illustrated in the figure 11. Based on the results reported here and also reports of others, we believe that melatonin may be a suitable candidate to be selected for treatment of acute or chronic Cd toxicity clinically, especially considering its safety margin and its low cost.
